Results 61 to 70 of about 13,781 (198)

Case Report: Hypomorphic Ligase 4 deficiency – a paradigm of immunodysregulation

Frontiers in Immunology
DNA Ligase 4 is critical to nonhomologous end joining, necessary for V(D)J recombination in T and B cell development. Ligase 4 deficiency is a rare autosomal recessive disorder caused by hypomorphic mutations in the DNA Ligase 4 gene, that can lead to a ...
Catarina Andrade, Ana Isabel Cordeiro, Marta Valente Pinto, Marta Valente Pinto, Conceição Neves, Catarina Martins, Jean-Pierre Villartay, João Farela Neves, João Farela Neves   +8 more
doaj   +1 more source

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

Annals of Neurology, Volume 100, Issue 4, Page 793-807, October 2026.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, for the CHIMES Study Group   +16 more
wiley   +1 more source

CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan, Zhexin Zhang, Jiaxin Wang, Roland Andersson, Daniel Ansari, Jinfei Chen   +5 more
wiley   +1 more source

Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Introduction Bispecific antibody (BsAb) treatment can lead to increased infections in myeloma patients. Methods We used ELISpot and flow cytometry to test the T cell response to BCMA‐CD3‐bispecific T cell engager (BiTE) pavurutamab (PAV) and BCMA‐expressing myeloma cells after in vitro culture.
Ida Steiro, Synne Stokke Tryggestad, Eli Svorkdal Hess, Hanne Hella, Pegah Abdollahi, Kari Lenita Falck Moore, Margrete Friestad, Magne Børset, Tobias S. Slørdahl, Anne Marit Sponaas   +9 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Diagnostic Immunization with Bacteriophage ΦX 174 in Patients with Common Variable Immunodeficiency/Hypogammaglobulinemia

Frontiers in Immunology, 2014
Purpose: Use of the T cell-dependent neoantigen bacteriophage ΦX 174 has been described since the 1960s as a method to assess specific antibody response in patients with primary immunodeficiencies.
Lauren L Smith, Rebecca eBuckley, Patricia eLugar   +2 more
doaj   +1 more source

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Matthew R. Schuelke, Julia Wang, Haley Newman, Evelyn Kurpiewski, Anne Reilly, Susan R. Rheingold, Gerald Wertheim, Moe Takeda, Daniel J. Zheng, Kaitlin Devine   +9 more
wiley   +1 more source

Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population‐Based Study of Patients With B‐Cell Malignancies

European Journal of Haematology, Volume 117, Issue 4, Page 1061-1071, October 2026.
ABSTRACT Background Bloodstream infections remain a major cause of mortality among cancer patients. Pathogen surveillance and risk stratification tools are key to improved management. This study describes trends in causative pathogens and explores risk factors for positive blood cultures (PBCs) and post‐infection mortality in cancer patients.
Mathias Holmsgaard Eskesen, Alexander Djupnes Fuglkjær, Tarec Christoffer El‐Galaly, Paw Jensen, Izabela Ewa Nielsen, Laurids Østergaard Poulsen, Mikkel Runason Simonsen, Kirstine Kobberøe Søgaard   +7 more
wiley   +1 more source

When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma

Clinical Case Reports
The association between systemic lupus erythematosus (SLE) and multiple myeloma (MM) is rare, with fewer than 20 cases reported in the literature, raising questions about the link between chronic immune dysregulation and oncogenesis.
Solohery Jean Noël Ratsimbazafy, Havantsoa Nomena Fandresena Andrianarisambatra, Rajo Païdia Radinasoa, Hitsy Andraina Razafindrazaka, Tahianasoa Randriamampianina, Rija Mikhaël Miandrisoa, Fidiarivony Ralison, Hanta Marie Danielle Vololontiana   +7 more
doaj   +1 more source